Related Experiment Video
Updated: Jan 14, 2026

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
Published on: March 1, 2022
The Risk of Hypertensive Disorders of Pregnancy in Inflammatory Bowel Disease
Lindsay M Clarke1, Sarah Hsu2, Deepti Pant3
1Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Introduction:
Inflammatory bowel disease (IBD) is prevalent during reproductive years. There are limited and conflicting data on whether IBD is associated with elevated risk of hypertensive disorders of pregnancy.
Methods:
We performed a single-center cohort study using electronic health records of singleton pregnancies delivered 1998-2016. The primary outcome was any hypertensive disorder of pregnancy, including either gestational hypertension or pre-eclampsia. Secondary outcomes included gestational hypertension, pre-eclampsia, preterm delivery, gestational diabetes, severe perineal laceration, and small or large for gestational age birth weight. We used generalized estimating equations, adjusted for age, 1st trimester body mass index and blood pressure, insurance, race, and parity to estimate associations between IBD and outcomes.
Results:
We included 364 pregnancies (266 individuals) with IBD and 45,048 pregnancies (32,189 individuals) without IBD. IBD was not associated with hypertensive disorders of pregnancy overall (adjusted odds ratio [aOR] 1.21 95% confidence interval [CI 0.81-1.82], P = 0.35). IBD was associated with an increased odds of pre-eclampsia (aOR 1.65 [95% CI 1.02-2.68]) but not gestational hypertension (aOR 0.82 [95% CI 0.42-1.57]). IBD was associated with preterm delivery (aOR 1.87 [95% CI 1.31-2.68]), small for gestational age (aOR 1.72 [95% CI 1.18-2.51]), and cesarean delivery (aOR 1.72 [95% CI 1.35-2.20]) but not with other secondary outcomes.
Discussion:
Although the risk of hypertensive disorders of pregnancy overall was not increased in pregnancies affected by IBD, there was an increased risk of pre-eclampsia. This may reflect underlying immune-mediated placental dysfunction.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

